HROG06 T0 M2 Cells

HROG06 T0 M2 is a primary human glioblastoma multiforme (GBM) cell line established from freshly resected tumor tissue of an adult patient diagnosed with WHO grade IV glioblastoma. The designation “T0” indicates that the tumor specimen was obtained at the initial surgical intervention, while “M2” refers to the second independently generated in vitro model derived from the same primary tumor. The cell line was developed within the HROG (Hansestadt Rostock Glioma) platform, which focuses on generating ultra-low passage glioma cultures that preserve the biological and molecular characteristics of the original patient tumor.

HROG06 T0 M2 grows adherently under standardized culture conditions and exhibits a spindle-shaped, fibroblast-like morphology typical of primary GBM cultures. Immunophenotypic analyses across the HROG series demonstrate expression of neural and glial lineage markers such as glial fibrillary acidic protein (GFAP), nestin, and vimentin, supporting astrocytic tumor origin. Molecular characterization within the HROG platform includes assessment of clinically relevant biomarkers such as MGMT promoter methylation status, EGFR amplification, and mutational profiling of genes including TP53, IDH1/2, KRAS, and BRAF, confirming preservation of tumor-associated genomic alterations in early passage cultures.

HROG06 T0 M2 has been used for in vitro evaluation of therapeutic responses to standard-of-care glioblastoma treatments, including alkylating chemotherapeutic agents, as well as targeted inhibitors. Comparative analyses within the HROG collection indicate stable morphology, reproducible growth kinetics, and consistent drug sensitivity profiles in early passages, supporting its suitability as a translational research model. As a patient-derived, low-passage GBM cell line, HROG06 T0 M2 provides a clinically relevant platform for studying glioblastoma biology, tumor heterogeneity, and mechanisms of treatment resistance.